Shares of Immunomedics Inc. are trading higher in Wednesday's after-hours market, following news the U.S. FDA gave accelerated approval to the company's Trodelvy to treat breast cancer.
At 6:31 p.m. EDT, the company's stock had gained 31.32% to trade at $28.85 a share. Volume in the after-hours market topped 1.3 million shares.
The company said Trodelvy, or sacituzumab govitecan-hziy, was approved for "the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
New York Yankees and Duke Basketball
